Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma

摘要: We present the case of a patient with rapidly accelerated fibrosarcoma gene F (BRAF) mutated adenocarcinoma lung, responding to BRAF inhibitor dabrafenib after progressing on vemurafenib followed by docetaxel. The illustrates potential benefit successful rechallenge inhibitor, well known phenomenon observed in other oncogenic driven molecular subtypes non-small cell lung cancer (NSCLC) such as epidermal growth factor receptor mutation. Rechallenge NSCLC should be considered, particularly absence alternative therpateutic options.